Table 1.

Clinical Trials involving various immune checkpoint inhibitors in hepatocellular carcinoma.

Name	Study	Detail	Phase	Sample	Primary Endpoint	Status
CTLA-4	NCT01853618	Tremelimumab with ablation	II	32	PR—26% Median TTP—7.4 mon Median OS—12.3 mon	Completed
	NCT02519348	Tremelimumab with Durvalumab	II	144	Safety and tolerability	Ongoing
PD-1	NCT01658878	Nivolumab vs. Placebo	I/II	262	OR—20% DOR—9.9 mo	Completed
	NCT02576509	Nivolumab vs. Sorafenib	III	726	Overall survival	Completed (Results awaited)
	NCT02702414	Pembrolizumab vs. Sorafenib	II	104	OS—26% Median OS—12.9 mon	Completed
	NCT02702401	Pembrolizumab vs. Placebo	III	408	Progression-free survival, Overall survival	Ongoing
	NCT03062358	Pembrolizumab vs. Placebo	III	330	Overall survival	Ongoing
	NCT03383458	Nivolumab vs. Placebo	III	530	Recurrence-free survival	Ongoing
	NCT02512773	Tislelizumab vs. Sorafenib	III	660	Overall survival	Ongoing
PD-L1	NCT03298451	Durvalumab vs. Durvalumab + Tremelimumab (regimen 1) vs. Durvalumab + Tremelimumab (regimen 2) vs. Sorafenib	III	1200	Overall survival	Ongoing
	NCT03434379	Atezolizumab + Bevacizumab vs. Sorafenib	III	480	Overall survival	Ongoing